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Abstract: With an increasing number of therapeutic drugs, the list of drugs that is responsible for severe pulmonary 
disease also grows. Many drugs have been associated with pulmonary complications of various types, including interstitial 
inflammation and fibrosis, bronchospasm, pulmonary edema, and pleural effusions. Drug-induced interstitial lung disease 
(DILD) can be caused by chemotherapeutic agents, antibiotics, antiarrhythmic drugs, and immunosuppressive agents. 
There are no distinct physiologic, radiographic or pathologic patterns of DILD, and the diagnosis is usually made when a 
patient with interstitial lung disease (ILD) is exposed to a medication known to result in lung disease. Other causes of ILD 
must be excluded. Treatment is avoidance of further exposure and systemic corticosteroids in patients with progressive or 
disabling disease. 
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INTRODUCTION 
 The lungs are a target for a variety of possible toxic 
substances because of their large contact surface. They can 
also act as a metabolism site for certain substances. Drugs 
can induce specific respiratory reactions or the lungs may be 
affected as part of a generalized response. More than 380 
medications are known to cause drug-induced respiratory 
diseases, the true frequency is unknown [1, 2]. The number 
of drugs, that cause lung disease, will undoubtedly continue 
to increase as new agents are developed. 
 To minimize the potential morbidity and mortality from 
drug-induced respiratory diseases, all health care providers 
should be familiar with the possible adverse effects of the 
medications they prescribe. The person-to-person variability 
of a drug response is a major problem in clinical practice and 
in drug development. The variability in drug response among 
patients is multifactorial, including extrinsic factors like 
environmental aspects and also genetic and intrinsic factors 
that affect the disposition of a certain drug. 
 Drug-induced lung injury may involve the airways, lung 
parenchyma, mediastinum, pleura, pulmonary vasculature, 
and/or the neuromuscular system. The most common form of 
drug-induced lung toxicity is drug-induced interstitial lung 
disease (DILD). Oral and parenteral routes of drug 
administration are most frequently cited as causing DILD; 
however, nebulized and intrathecal administration have been 
also been implicated. Pulmonary drug toxicity may result 
from a direct or indirect drug effect. Direct effects may be  
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either idiosyncratic or due to a toxic reaction of the drug or 
one of its metabolites. 
 Recognition of drug-induced lung disease, however, is 
difficult because the clinical, radiological, and histological 
findings are nonspecific. The connection with drug use and 
the development of related inflammatory damage or 
idiosyncratic toxicities is hard to recognize and objectify, 
especially in those cases using multiple drugs [3]. 
EPIDEMIOLOGY 
 Many drugs are effective in only 25 to 60 percent of 
patients, and more than 2 million cases of adverse drug 
reactions occur annually in the United States, including 
100.000 deaths [4-6]. Hitchen et al. reported that adverse 
drug reactions (ADR) are the cause of 250.000 
hospitalizations per year in the United Kingdom [7]. A 
Swedish study has implicated adverse drug reactions as 7th 
most common cause of death [8]. A large prospective study 
of adverse drug reaction in UK hospital in-patients suggests 
that at least 1 in 7 in-patient episodes is complicated by an 
adverse drug reaction and the incidence of 14.7% is 
comparable with previous studies [9]. In UK, 0.9% of total 
hospital admissions represent adverse drug reaction-
associated admissions [10]. Over the period between 1999 
and 2008 the annual number of adverse drug reactions 
increased by 76.8%, and in-hospital mortality rate increased 
by 10%. An estimated calculation in the Netherlands showed 
that about 430 million euros could be saved each year when 
side effects are reduced [6]. In the United States, an 
estimated 0.3% of hospital deaths are drug related [5]. Up to 
10% of patients who receive chemotherapeutic agents 
develop an ADR in their lungs [11]. Exact frequency of 
drug-induced pulmonary toxicity is unknown. Several 
studies suggest that drug-induced pulmonary toxicity is 
underdiagnosed worldwide. Global incidence of interstitial 
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lung disease (ILD) is not clearly known but 2.5-3% of cases 
are drug induced [12, 13]. The list and frequency of toxicity 
of all drugs implicated in lung injury can be found elsewhere 
[14]. 
RISK FACTORS FOR DILD 
 The likelihood of developing adverse pulmonary effects 
secondary to drugs remains largely unpredictable and 
idiosyncratic. Patients likely to develop DILD are those 
receiving chemotherapy, those with inflammatory conditions 
such as rheumatoid arthritis and inflammatory bowel disease, 
and those receiving concurrent multiple toxic agents. Some 
of the known risk factors are as follows: 
Age 
 In general, both extremes of age (i.e. childhood and old 
age) are associated with an increased risk of drug toxicity. 
The elderly patient is more prone to develop severe side 
effects, partly because of the fact that the excretory function 
of the kidney is lower, the liver blood perfusion is 
diminished and the overall metabolic function is changed. 
For instance, Simpson et al. [15] showed in a retrospective 
review of bleomycin pulmonary toxicity, that the fatal cases 
of pulmonary toxicity were older than the remaining patients 
and for patients aged over 40 years, especially those with 
renal function in the lower range of normal, the risk of 
developing fatal toxicity may exceed 10%. 
Sex 
 In long-term nitrofurantoin prophylaxis, a chronic form 
of pulmonary reactions has been reported to occur after 8 
months to 16 years of treatment [16]. Most of those affected 
have been elderly and most have been females. However at 
yet, there is no scientific evidence in the literature that the 
gender influences the risk of DILD. 
Ethnicity 
 There may be racial differences in the incidence of 
DILD. In Japan, cases of lung diseases presumably induced 
by gefitinib have provided important findings, including 
evidence about racial differences in the DILD and 
pathological variety of the lung diseases [17]. However, it is 
difficult to determine the relative incidence of DILD during 
the drug-development phase, because the events are too rare 
and the sample sizes are too small to make reliable estimates 
from the results of clinical studies. Acute and organizing 
diffuse alveolar damage associated with Bortezomib were 
also first reported in Japan and subsequently in African 
American patients with severe pneumonitis [18, 19]. Ethnic 
influences could be also observed by leflunomide and 
tacrolimus [20, 21]. Genetic polymorphisms may help 
explain why some groups of patients have the expected 
response to pharmacotherapy whereas others experience 
toxicity or therapeutic failure [22-26]. 
Dose 
 In several cases, such as therapies with amiodarone, 
bleomycin or BCNU, the dose has been found to be a risk 
factor for a drug to cause ILD [1, 27-31]. Although this 
affirmation is not universal, physicians should keep in mind 
this possibility and monitor a drug dose according to the 
published information. 
Oxygen 
 Lung tissue is vulnerable to the toxic effects of oxygen 
and oxygen damage readily occurs. The lungs are normally 
equipped with an extensive antioxidant network to protect 
against tissue damage by reactive oxygen species. This 
network may be insufficient and this situation of inadequate 
protection is called oxidative stress. It is striking that 
numerous conditions that lead to ILD may cause reactive 
oxygen species and result in oxidative stress [32]. Disruption 
of the oxidant/antioxidant balance is important in the 
pathogenesis of acute lung injury and acute respiratory 
distress syndrome (ARDS) [33]. Amiodarone is damaging to 
the lungs via transfer of electrons to O2. 
Drug Interaction 
 The role of drugs taken concomitantly may be important. 
Drugs in the same therapeutic class can often induce similar 
pulmonary toxicity pattern [34]. Hazardous associations 
have been reported with the coadministration of cisplatin and 
bleomycin, which can increase the risk of bleomycin-
induced interstitial lung disease. The combination therapy of 
gemcitabine and bleomycin is very toxic too. 
Radiation 
 DNA damage and repair proteins are involved in many 
types of lung injury and repair. Radiation can be injure the 
lung by this mechanisms and radiation therapy in 
combination with chemotherapy may be synergistic [1]; for 
instance, conjoint radiation therapy is associated with high 
rates of lung toxicity by bleomycin. Interstitial pneumonitis 
after fractionated total body irradiation in preparation for 
allogenic bone marrow transplantation occurred with a 
significant incidence of 20% [35]. 
Underlying Lung Disease 
 Preexisting lung disease as an important risk factor is 
controversial. A large-scale prospective case-control study of 
risk factors of acute lung diseases/interstitial pneumonia was 
performed in a cohort of patients with non small lung cancer 
who had or had not been treated with gefitinib [17]. By 
logistic regression analysis, the following risk factors were 
identified to be most commonly associated with a poor 
prognosis: age  65 years, smoking habit, reduced lung 
function and pre-existing interstitial pneumonia. The hitherto 
existing literature states the prevalence of methotrexate 
pneumonitis to be 3.5-7.6% [36-38]. Sathi N et al. designed 
the largest ongoing prospective study and the results suggest 
that methotrexate pneumonitis does not occur as often as 
previously thought with an incidence of one case every 192 
patient years [39]. Furthermore, ILD is reported in 1% of 
those taking leflunomide and 0.6% of patients receiving 
etanercept [40, 41]. The possible link between leflunomide 
and ILD has evoked increasing concern. 1.2 % in Japanese 
patients with rheumatoid arthritis who received leflunomide 
developed de novo or exacerbated ILD; and pre-existing ILD 
was the most important risk factor for leflunomide-induced 
ILD [42]. On the other hand, Suissa et al. [20] conducted a 
population-based epidemiologic study and concluded that 
patients treated with leflunomide who have no history of 
methotrexate use and no existing ILD carry no excess risk of 
ILD. The increase in the risk of ILD associated with 
leflunomide is restricted to the subgroup of patients with a 
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history of methotrexate use or existing ILD (relative risk 
2.6), and this appears to be the result of channeling bias. 
CAUSES OF DRUG-INDUCED INTERSTITIAL LUNG 
DISEASE 
 The major representatives of DILD include cytotoxic, 
cardiovascular, anti-inflammatory, antimicrobial, biological 
agents and miscellaneous drugs (Table 1): 
Table 1. Drugs Associated to the Development of Interstitial 
Lung Disease 
 
Antimicrobial Agents 
 Amphotericin B 
 Isoniazid 
 Nitrofurantoin 
 Sulfasalazine 
Anti-Inflammatory Agents 
 Aspirin 
 Etanercept 
 Gold 
 Infliximab 
 Methotrexate 
 Nonsteroidal anti-inflammatory drugs 
 Penicillamine 
Biological Agents 
 Adalimumab 
 Alemtuzumab 
 Bevacizumab 
 Cetuximab 
 Rituximab 
 Trastuzumab 
 Tumor necrosis factor (TNF)-  blockers 
Cardiovascular Agents 
 ACE inhibitors 
 Amiodarone 
 Anticoagulants 
 ß-Blockers 
 Flecainide 
 Hydrochlorothiazide 
 Procainamide 
 Statins 
 Tocainide 
Chemotherapeutic Agents 
 Azathioprine 
 BCNU 
 
 
 
(Table 1) contd….. 
Chemotherapeutic Agents 
 Bleomycin 
 Bortezomib 
 Busulfan 
 Carmustine 
 Chlorambucil 
 Colony-stimulating factors 
 Cyclophosphamide 
 Cytarabine 
 Deferoxamine 
 Docetaxel 
 Doxorubicin 
 Erlotinib 
 Etoposide 
 Fludarabine 
 Flutamide 
 Gefitinib 
 Gemcitabine 
 Hydroxyurea 
 Imatinib 
 Interferons 
 Lomustine 
 Melphalan 
 Methotrexate 
 Methyl-CCNU 
 Mitomycin-C 
 Nitrosoureas 
 Paclitaxel 
 Procarbazine 
 Thalidomide 
 Vinblastine 
 Zinostatin 
Miscellanous 
 Bromocriptine 
 Carbamazepine 
 Cabergolide 
 Methysergide 
 Penicillamine 
 Phenytoin 
 Sirolimus 
 Talc 
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Cytotoxic Drugs 
 Any chemotherapeutic drug can adversely affect the 
lung, but the drugs most commonly implicated in lung 
toxicity are bleomycin, carmustine, busulfan, and 
cyclophosphamide [43-46]. Approximately 1-10% of 
patients taking one of these drugs are affected. Bleomycin is 
the drug most commonly studied as a cause of DILD. Larger 
studies have shown that rates of 8-10% with some degree of 
lung injury have been observed [47]. Symptoms may 
develop earlier than 4 weeks and later than 10 weeks 
following chemotherapy and the damage is predominantly at 
the lung base. Busulfan toxicity causes drug-induced 
pulmonary damage after prolonged exposure, usually after 3-
4 years of therapy [48]. Cyclophosphamide causes early-
onset ILD with a low incidence, estimated at less than 1%, 
but cyclophosphamide may also cause later damage [48]. 
Cardiovascular Agents 
 Amiodarone is the most common drug related to 
cardiovascular pulmonary abnormalities. It affects as many 
as 6% of individuals receiving the drug and, amongst these 
cases, fatality rates range from 10-20% [49]. Statin-induced 
DILD has been reported with most statins, suggesting that 
statin-induced ILD is a class effect and not a specific statin 
effect [50]. 
Anti-Inflammatory Drugs 
 Aspirin is the most common anti-inflammatory drug 
associated with ADR. An ARDS-type syndrome has been 
described with salicylate toxicity [51]. Methotrexate is 
increasingly used as an anti-inflammatory agent to treat 
many disorders. Pulmonary reaction to methotrexate is 
commonly subacute, with a hypersensitivity-like 
manifestation [52]. Important drugs with potential DILD are 
gold, penicillamine, azathioprine and nonsteroidal anti-
inflammatory drugs (NSAIDs) [53]. NSAIDs may cause 
acute pulmonary hypersensitivity reactions resulting in 
bilateral interstitial infiltration and eosinophilic pneumonia. 
Onset of such a reaction can occur within the first week and 
up to three years after first exposure [51]. 
Antimicrobial Agents 
 Nitrofurantoin, amphotericin B, sulfonamides, and 
sulfasalazine are known to cause DILD. For example, 
nitrofurantoin is associated with acute or chronic pulmonary 
injury. The acute manifestation of this process is the most 
common and is thought to be due to a hypersensitivity 
reaction from the drug. The chronic form includes 
pulmonary fibrosis and BOOP [54]. 
Biological Agents 
 The development and production of biological agents has 
grown rapidly over the last 10 years and represented 22% of 
all new chemical entities approved for use by United States 
or European Union regulatory authorities [55, 56]. Classes of 
biological agents with reported DILD include tumor necrosis 
factor (TNF)-  blockers, anti-CD20 antibodies, recombinant 
interferon (INF) alpha, T-cell antiproliferative agents, or 
others like cetuximab, bevacizumab, alemtuzumab or 
trastuzumab [57-59]. 
 
Miscellaneous Drugs 
 Bromocriptine has been reported to cause pulmonary 
fibrosis and pleural disease [60]. Belmonte et al. reported of 
pleuropulmonary toxicity of cabergoline, an ergoline 
derivate in the treatment of Parkinson`s disease [61]. 
MECHANISMS IN PULMONARY TOXICOLOGY 
 The mechanism of DILD is not fully understood. 
Pulmonary toxicology can be divided in two broad 
categories based on the route of exposure to the offending 
agent. Alveolar and bronchial epithelial cells may be injured 
by inhalation of a drug or through the vasculature system 
[13, 62-64]. Various reasons may be put forward to explain 
why certain drugs cause toxicity specifically in the lungs: (1) 
Some substances reach higher cell or tissue concentrations in 
the lung than in other organs. (2) A specific pattern or extent 
of bioactivation occurs in the lung. (3) The consequences of 
bioactivation are lung-specific. Furthermore, some foreign 
compounds may accumulate preferentially in lung tissue 
[49]. 
 Lung injury that is induced by pneumotoxic agents gives 
rise to alveolitis and edema. In response to injury to the lung 
parenchyma, there is an immediate requirement to initiate 
tissue repair and restore barrier function. Acute injury may 
progress to chronic inflammation and eventually lead to 
fibrotic change that ultimately interferes with gas exchange. 
Chemotherapeutic drugs can additionally cause a direct toxic 
reaction, and direct toxicity usually occurs over time before 
manifesting clinically [65- 69]. -induced pulmonary fibrosis 
[69]. 
 Most chemicals do not cause cell toxicity directly; 
usually some form of biotransformation is required for 
chemical agents to cause cell injury. This biotransformation 
process may increase the toxicity of chemicals by producing 
reactive metabolites. If these reactive metabolites are not 
readily removed by enzymatic or nonenzymatic reactions, 
they may cause cell injury and death [67, 70]. 
 The concept that some drugs may cause oxidative stress 
and that their toxicity may be enhanced by the (therapeutic) 
administration of oxygen is of paramount importance in 
clinical settings [71]. A disturbance of oxidant/antioxidant 
system homeostasis may occur. The resulting toxic oxygen 
species depletes the reducing equivalents and generates 
oxidative stress [16, 72-74]. 
 Furthermore, we know two other pathophysiologic 
principles in pulmonary toxicity [75]. First, drugs can act as 
potential antigens, or haptens, inducing an immune cascade 
that can lead to immune-mediated lung toxicity. 
Hypersensitivity reactions do not show a simple dose-
response relationship and require prior sensibilisation to the 
drug. The immune damage to the lung may be due to drug-
specific antibodies or, more likely, drug-specific T cells. 
Deposition of antigen-antibody complexes may trigger an 
inflammatory response, leading to pulmonary edema and 
interstitial lung disease. Drug-induced systemic lupus 
erythematodes is an example of immune-mediated lung 
damage. Secondly, similar to other amphiphilic compounds, 
some drugs can cause a deposition of phospholipids within 
cells. For example, amiodarone has been demonstrated to  
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produce phospholipidosis in alveolar macrophages and in 
type 2 cells. 
HISTOLOGIC FINDINGS 
 As the name implies, the histological abnormalities that 
characterize DILD generally involve the pulmonary 
interstitium to a greater extent than the alveolar spaces or 
airways. Generally when the interstitium acts to any drug 
injury, the lung must respond to the damage and repair itself. 
If the exposure persists or if the repair process is imperfect, 
the lung may be permanently damaged, with increased 
interstitial tissue replacing the normal capillaries, alveoli, 
and intact interstitium. Histological changes for most drug 
reactions are nonspecific, but a limited number of drugs (e.g. 
amiodarone) produce a characteristic histopathological 
pattern of involvement, which enables almost instant 
recognition of the drug etiology (Table 2). For instance, 
methotrexate causes an acute granulomatous ILD which 
mimics an opportunistic infection [73]. 
Table 2. Histopathologic Manifestations of Pulmonary 
Reactions to Noncytotoxic Drugs 
 
Interstitial pneumonia 
Hypersensitivity pneumonia 
Bronchiolitis obliterans organizing pneumonia 
Granulomatous pneumonitis 
 
 Drugs can produce virtually all histopathological patterns 
of interstitial pneumonia, including hypersensitivity 
pneumonitis (HP), organizing pneumonia (OP), diffuse 
alveolar damage (DAD) and nonspecific interstitial 
pneumonia (NSIP), eosinophilic pneumonia, bronchiolitis 
obliterans organizing pneumonia (BOOP), pulmonary 
hemorrhage, and granulomatous pneumonitis [3]. Most drugs 
of a comparable class may induce a similar pattern of 
pulmonary involvement, suggesting a common cytopathic 
mechanism. But some drugs can produce more than one 
pattern of histopathological involvement in the same patient. 
These reactions can manifest acutely, subacutely, or 
chronically (Table 2 and Fig. 1). 
Hypersensitivity Pneumonitis (HP) 
 Drug hypersensitivity results from interactions between a 
pharmacologic agent and the human immune system. 
Histological the signs of interstitial pneumonia are found 
with infiltration of the interstitial space by lymphocytes and 
plasma cells. At this point other interstitial pneumonias have 
to be considered. Another important feature of HP is the 
occurrence of small interstitial non-caseating granulomas 
with variable numbers of giant cells, for example causing by 
anti-TNF agents, methotrexate and BCG therapy (Table 3 
and Fig. 1a). 
Organizing Pneumonia 
 The characteristic histological finding of OP is the 
occurrence of intra alveolar fibroblastic proliferations with 
production of immature collagen. The lung architecture is 
typically preserved, and lymphocytes, plasma cells, and 
histiocytes are present to a variable degree within the  
 
(a) 
 
(b) 
 
(c) 
 
(d) 
 
Fig. (1). Characteristic histological patterns (Hematoxylin & Eosin 
staining in 100-200x magnification) in drug-induced interstitial 
lung disease, for example. (a) Hypersensitivity Pneumonia (a 
moderate chronic interstitial inflammation-the infiltrate consists of 
lymphocytes, plasma cells and multinucleated giant cells). (b) 
Organizing Pneumonia (airspaces are partially occupied by 
fibroblastic proliferations with collagen production). (c) Non 
specific interstitial Pneumonia (a homogeneous fibrotic broadening 
of the alveolar septa is seen with mild chronic inflammation, 
accompanied by hyperplasia of type II pneumocytes. (d) Usual 
interstitial Pneumonia (lung parenchyma with so-called 
honeycombing pattern-the lesion is characterized by cystic 
spaceswhich are surrounded by a dense fibrotic tissue. 
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interstitium. Nodular organizing pneumonia is typically seen 
in patients exposed to bleomycin, in the form of round-
shaped foci that localize mainly in lung bases, but may abut 
the pleura and simulate metastatic nodules (Fig. 1b). 
Interstitial Pneumonia 
 Interstitial pneumonia, the most common manifestation 
of DILD, is an inflammation of the lung interstitium, such as 
alveolar septa. Drug-induced NSIP is a relatively common 
pulmonary reaction to drugs (Table 3). The typical pattern of 
NSIP is a uniform process affecting the lung homogenously 
suggesting a temporally uniform process. Lymphocytes, 
lymphoid aggregates and plasma cells infiltrate the alveolar 
septa and the peribronchial spaces. Interstitial fibrosis is also 
found [76 -78]. In drug-induced NSIP (Fig. 1c), interstitial 
inflammation is typically more homogeneous and more 
cellular than that seen in cases of usual interstitial 
pneumonia (UIP) (Fig. 1d). A wide array of drugs can cause 
interstitial pneumonia [2]. For example, the most common 
type of DILD due to anti-TNF agents is diffuse interstitial 
lung disease or pulmonary fibrosis, reported at 0.5 to 0.6% 
of at-risk patients [41, 79, 80]. 
Bronchiolitis Obliterans Organizing Pneumonia 
 BOOP shows organized polypoid granulation 
inflammatory tissue in the distal bronchiole airways, 
respiratory bronchioles, alveolar ducts, and alveoli (Table 3). 
There is no disruption of the lung architecture and there is no 
traction bronchiectasis and no histological honeycombing 
[81]. 
Granulomatous Pneumonitis 
 Some drugs are capable of producing a granulomatous 
inflammation without necrosis (Table 3). These agents can 
induce a granulomatous pneumonitis with or without the 
bronchiolitis and interstitial inflammation seen in HP [82]. 
DIAGNOSTIC PROCEDURES 
 The diagnosis of DILD is mainly one of exclusion and 
requires the meticulous ruling out of all other possible 
causes. Unfortunately, therapeutic agents that cause DILD 
are often used to treat disease that can result in diffuse 
interstitial lung changes. It is, therefore, frequently difficult 
to determine if pulmonary abnormalities are related to the 
underlying disease or due to the medication. Discontinuance 
of the offending agent is often followed by spontaneous  
 
improvement, whereas failure to appreciate the causal 
relationship between the drug and the pulmonary disease can 
lead to irreversible lung injury or death. The diagnosis of 
DILD is usually based on several criteria [83-85]: (1) A 
history of drug exposure with correct identification of the 
drug, its dose, and its duration of administration. (2) Clinical, 
imaging and histopathological patterns which are consistent 
with earlier observations with the same drug. (3) Exclusion 
of other lung disease. (4) Improvement following 
discontinuation of the suspected drug and (5) Recurrence of 
symptoms on rechallenge, but rechallenge can be hazardous. 
 Numerous methods for causality assessment of ADR 
have been published and are falling into three categories: 
expert judgements, algorithms and probabilistic methods 
[86]. Expert judgements are individual assessments based on 
previous knowledge and experience in the field using no 
standardized tool to arrive at conclusions regarding causality. 
Algorithms are sets of specific questions with associated 
scores for calculating the likelihood of a cause-effect 
relationship. Bayesian approaches use specific findings in a 
case to transform the prior estimate of probability into a 
posterior estimate of probability of drug causation. 
Unfortunately, there is still no method universally accepted 
for causality assessment of ADR. 
 An objective assessment of the patient`s baseline 
pulmonary status, as well as treatment history, is crucial to 
differentiate drug-induced pathology from the primary 
process. Diagnostic work-up should include a careful 
examination, laboratory studies, chest radiography and/or 
high-resolution CT (HRCT) of the chest, pulmonary function 
testing and-if necessary-invasive procedures such as 
bronchoscopy. Other non-invasive studies that may be 
helpful include an echocardiogram, sputum Gram stain and 
culture, and immunologic studies excluding vasculitis and 
connective tissue diseases. 
 The comparison of the observed case and previous cases 
is a very important part of diagnostic procedure. The 
spontaneous reporting system in pharmacovigilance is a 
process of collecting, assessing, presenting and interpreting 
suspected ADR. Causality assessment in pharmacovigilance 
may involve making decision based on the information on 
the relationship between a drug exposure and suspected 
ADR from a single adverse event or aggregated date. 
Standardized causality assessment is now a routine 
procedure at pharmacovigilance centers around the world 
[87]. 
 
Table 3. Drugs with Toxic Pulmonary Effects 
 
Condition Drug 
Interstital pneumonia 
Adalimumab, Amphotericin B, Amiodarone, Azathioprine, Bleomycin, Busulfan, Chlorambucil, 
Cyclophosphamide, Etanercept, Flecainide, Gold, Interferon alfa, Interferon beta, Infliximab, Melphalan, 
Methadone, Methotrexate, Mexiletine, Nitrofurantoin, Paclitaxel, Penicillamine, Phenytoin, Rituximab, 
Sirolimus, Statins, Sulfasalazine, 
Hypersensitivity pneumonitis Azathioprine, 6-Mercaptopurine, beta-blockers, Busulfan, Fluoxetine, Nitrofurantoin, Procarbazine 
Bronchiolitis obliterans organizing pneumonia Amiodarone, Amphotericin, Bleomycin, Carbamazepine, Cocaine, Cyclophosphamide, Interferon alfa, 
Interferon beta, Methotrexate, Penicillamine, Phenytoin, Sulfasalazine, Tetracyclines 
Granulomatous pneumonitis Cocaine, Cromolyn sodium, Fluoxetine, Methotrexate, Nitrofurantoin, Pentozocine, Procarbazine 
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Clinical Signs/Symptoms and Physical Examination 
 Many of the DILD have similar clinical features and are 
not easily distinguished on examination. Time to onset is from 
a few days to years and is unpredictable. The onset of the 
disease may be progressive over a few weeks, with isolated 
fever followed by the insidious development of respiratory 
symptoms, or the onset may be abrupt. Acute pneumonitis 
secondary to drug therapy can present with acute 
breathlessness occurring over several hours or days. Fever, 
rash, wheeze and peripheral eosinophilia are features of these 
reactions. The chronic form of the disease manifests as 
decreased exercise tolerance mainly as a result of progressive 
dyspnea. In the case of pulmonary hemorrhage, patients 
usually present with hemoptysis, dyspnea, hypoxemia, and 
acute anemia. It is also important to be aware that DILD may 
be enhanced by other factors such as age, impaired renal 
function, smoking and radiation therapy [88]. 
 The physical findings of DILD are nonspecific. Physical 
examination reveals crackles on respiratory examination and 
may include digital clubbing. Signs of pulmonary 
hypertension with right ventricular dysfunction, such as 
lower-extremity edema or jugular venous distention, can 
occur late in the course and are not helpful in diagnosing a 
specific DILD. 
Laboratory Studies 
 In general, laboratory analyses do not help in establishing 
the diagnosis. The white blood count may show increased 
eosinophils in cases of drug-induced pulmonary 
eosinophilia. However, the absence of peripheral 
eosinophilia does not exclude a diagnosis of drug-induced 
eosinophilic pneumonia. In the case of HP, peripheral 
eosinophilia may be present. Testing for antinuclear 
antibodies, anti-cytoplasmatic antibodies and anti-glomerular 
basal membrane autoantibodies is essential to classify drug-
induced DAH (autoimmune vs non-autoimmune), and to 
separate drug-induced DAH from DAH related to a naturally 
occurring systemic illness [89], for example the 
determination of anti-cytoplasmatic antibodies may be 
appropriate for the drug PTU. 
Radiology 
 Generally, it is difficult to infer the histopathological 
background of the drug reaction from the pattern on imaging 
[90-98]. HRCT is more sensitive than chest radiography for 
defining the radiographic abnormalities, but is rarely specific 
for a drug etiology [99, 100]. One study reported abnormal 
findings on HRCT in all patients and abnormal findings on 
radiography in 74% [96]. On the other hand, the changes of 
classic radiation pneumonitis develop 1-2 months after the 
beginning of treatment in the form of a discrete haze, ill-
defined patchy nodules or an area of condensation with 
volume loss. The changes predominate in the irradiated area 
[101]. 
 The pattern of involvement did not always correspond to 
the underlying histological findings and include NSIP, UIP, 
HP or BOOP (Fig. 2). Conclusively, HRCT is of limited 
value in determining the prognosis, and should be only 
performed in accordance with established guidelines and 
interpreted by a radiologist experienced in the evaluation of 
diffuse lung disease [102, 103]. 
(a) 
 
(b) 
 
(c) 
 
Fig. (2). Radiologic examples of drug induced interstitial lung 
disease, for example. (a) Bronchiolitis obliterans organizing 
Pneumonia. (b) Non specific interstitial Pneumonia. (c) Usual 
interstitial Pneumonia. 
Non-Specific Interstitial Pneumonia 
 HRCT most often shows patchy ground-glass opacities or 
consolidation and irregular reticular opacities [96]. Typically 
70    The Open Respiratory Medicine Journal, 2012, Volume 6 Schwaiblmair et al. 
these have a peripheral and basilar predominance. NSIP is 
mostly caused by amiodarone, methotrexate, and carmustine 
[100]. Lung parenchymal opacities in amiodarone have 
increased attenuation and this finding is suggestive, but it is 
not pathognomic of amiodarone-induced pulmonary toxicity 
(Fig. 2b). 
Usual Interstitial Pneumonia 
 Cytotoxic chemotherapeutic agents, such as bleomycin 
and methotrexate, are the most common cause of UIP. Early 
high-resolution CT scans may show only scattered or diffuse 
areas of ground-glass opacity. Later, findings of fibrosis 
(traction bronchiectasis, honeycombing) predominate in a 
basal distribution. The predominance feature on HRCT is 
fibrosis that leads to subpleural cystic airspaces with thick 
walls that is known as “honeycombing” (Fig. 2c). Ground 
glass abnormalities, increased attenuation of the lung tissue 
without distortion of the underlying blood vessels or bronchi, 
are absent or minimal in classic UIP. 
Hypersensitivity Pneumonia 
 Several drugs, for instance cyclophosphamide, 
sulfonamides or nonsteroidal anti-inflammatory drugs, can 
result in a hypersensitivity reaction in the lungs. Bilateral 
patchy ground-glass opacities with upper lobe-predominant 
centrilobular ill-defined nodules are the most common 
HRCT finding. In chronic disease, features of NSIP or UIP 
with fibrosis may predominate. 
Bronchiolitis Obliterans Organizing Pneumonia 
 HRCT findings of BOOP show patchy ground-glass 
opacities with airbronchogramms and usually located 
peripherally (Fig. 2a). They may be triangular-shaped with 
the base of the triangle on the pleural surface. There are 
more than 35 drugs that cause BOOP including minocycline, 
bleomycin, amiodarone, phytoin, and the interferons [81]. 
Pulmonary Function Testings 
 The above-mentioned pathologic abnormalities can lead 
to profound impairment in lung physiology. Pulmonary 
function testing (PFT) can vary from an obstructive 
ventilatory defect due to bronchospasm or bronchiolitis 
obliterans to restrictive physiology with diffusion 
impairment secondary to pulmonary fibrosis. Most drugs 
cause a restrictive lung disease pattern with decreased total 
lung capacity (TLC), residual volume (RV), forced vital 
capacity (FVC), and diffusing capacity (DLCO) reflecting a 
pathologic disturbance of the alveolar-capillary interface 
[104]. The forced expiratory volume in one second (FEV1) to 
FVC ratio (FEV1/FVC ratio) may be normal or increased. 
However, drugs that cause bronchiolitis obliterans may cause 
an obstructive ventilatory defect (reduced FEV1/FVC ratio 
and FEV1, increased RV and RV/TLC ratio). 
 Gas exchange is impaired due to ventilation-perfusion 
mismatching and decreased diffusion across the abnormal 
interstitium. Arterial blood gas analysis may reveal 
hypoxemia at rest. Patients with DILD should have also 
arterial oxygen saturation determined during exertion, 
because many patients with only mild disease desaturate 
with exertion despite normal saturation at rest. 
 
Bronchoscopy 
 Bronchoscopy with bronchoalveolar lavage (BAL) is a 
minimally invasive, well-tolerated clinical tool that can be 
useful in evaluating patients who have diffuse infiltrative 
lung disease. Although it is infrequently diagnostic by itself, 
when combined with clinical data and radiographic imaging, 
a likely diagnosis often can be reached [105]. The results of 
BAL cell differentials with a lymphocytic (  15%), a 
neutrophilic (  3%), an eosinophilic ( 2%), or a mixed 
cellular pattern can be used as an adjunct to diagnosis [106, 
107]. BAL findings in drug-induced HP include 
lymphocytosis, a low CD4 to CD8 ratio, and occasionally, an 
increase in neutrophils. Eosinophilic pneumonia is typified 
by an elevated eosinophilic count in the BAL fluid [108]. 
Cytotoxic pneumonitis due to chemotherapeutic agents 
typically has a neutrophil predominance. BAL findings in 
drug-induced BOOP show increased lymphocytes. 
Exceptionally some drugs cause characteristic changes in the 
BAL, for example amiodarone with changes in the alveolar 
macrophage population, which shows foamy 
intracytoplasmic alterations and corresponds to a form of 
phospholipidosis [49]. Unfortunately, these findings indicate 
medication exposure and do not necessarily establish drug 
toxicity. Table 4 describe typical BAL findings in DILD due 
to several agents. 
Table 4. Bronchoalveolar Lavage (BAL) Cell Differentials as 
an Adjunct to Diagnosis (Adapted from 108 and 109) 
 
Typical BAL Findings Examples 
Idiopathic pulmonary fibrosis 
Acute respiratory distress syndrome 
Connective tissue disorders 
Asbestosis 
Neutrophilic 
Wegener`s granulomatosis 
Allergic bronchopulmonary aspergillosis 
Churg Strauss syndrome 
Eosinophilic pneumonia 
Eosinophilic 
Idiopathic hypereosinophilic syndrome 
Sarcoidosis 
Berylliosis 
Hypersensitivity pneumonitis 
Silicosis 
Lymphocytic 
Crohn disease 
BOOP 
Connective-tissue disease Mixed cellularity 
Nonspecific interstitial pneumonia 
 
 Although open lung biopsies are not pathognomonic for 
drug toxicity and correlation with clinical, laboratory, and 
radiologic data is required, they can be a tool in the 
evaluation of suspected DILD by helping to exclude  
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underlying disease or infection and documenting the pattern 
of lung injury. The latter information is helpful in making 
the diagnosis of drug toxicity as well as guiding the optimal 
management of the patient. Moreover, there are exceptions 
with characteristic histological findings, such free foamy 
macrophages supporting the diagnosis of amiodarone 
pulmonary toxicity. Although a surgical lung biopsy might 
allow the pathologist to give a more complete description of 
the pulmonary process, a minimally-invasive procedure, 
such as BAL or bronchoscopic biopsy, can contribute 
valuable data [2, 109-111]. Mostly, the amount of lung tissue 
obtained by transbronchial biopsy is very small and their 
findings, particularly those that are themselves non-specific, 
should not be anyway considered diagnostic. Cockerill and 
colleagues [112] found that 20% of patients with diffuse 
infiltrates who underwent surgical lung biopsy had 
pathologic findings that could be attributed to a drug 
reaction. In the study of Romagnoli et al., transbronchial 
lung biopsy samples were considered adequate and 
diagnostic, and confirmed the diagnosis of DILD in 76% of 
the cases [111]. Furthermore, correlations of the histology 
with HRCT by pathologists and radiologists have 
contributed to our knowledge [93, 98]. 
TREATMENT 
 The primary goal of treatment is to suppress the 
inflammatory response and prevent the deposition of fibrotic 
tissue. The management strategy depends on the severity of 
the disease. In the first step, the medication should be 
withdrawn and the treatment of DILD consists appropriately 
managing of pulmonary symptoms, after other possibilities 
are eliminated and DILD is highly suspected. Ideally, 
symptoms should remit and management includes supportive 
care. Acute episodes of drug-induced pulmonary disease 
usually disappear 24-48 hours after the drug has been 
discontinued, but chronic syndromes may take longer to 
resolve. Because hypoxemia is common in DILD, 
supplemental oxygen therapy is often prescribed. 
 Secondly, if the cytotoxic drug-induced disease is severe 
or appears to progress despite elimination of further drug 
exposure, an empirical course of glucocorticoids is 
advisable. In certain DILD such as BOOP, eosinophilc 
pneumonia, and HP, there is evidence that corticosteroids 
may hasten resolution of symptoms. Drug induced acute 
eosinophilic pneumonia generally responds to drug 
withdrawal and corticosteroid therapy, but tends to relapse if 
the patient is rechallenged with the drug, especially in the 
context of early corticosteroid withdrawal. Thirdly, in other 
entities such as pulmonary fibrosis, corticosteroids have no 
role, and the disease may be progressive even after 
withdrawal of the offending agent. If a patient is 
rechallenged with the drug, symptoms may or may not recur. 
This is a decision that has to be carefully weighed depending 
on the severity of the drug-related pulmonary toxicity and 
the morbidity associated with not treating the underlying 
disease. If alternative agents are available, they should be 
used. 
 Because many patients with DILD are treated with 
immunosuppressive medications and are at some modest 
increased risk for the development of infections, patients 
with DILD should receive a pneumococcal vaccine and a 
yearly influenza virus vaccine. Furthermore, tuberculosis 
may be associated with anti-tumor necrosis factor 
monoclonal antibody therapy. The increased risk with early 
anti-TNF treatment and the absence of correct 
chemoprophylactic treatment favor the reactivation of latent 
tuberculosis [113]. Greater awareness is necessary of 
patients with risk factors, particularly ethnicity, to facilitate 
more appropriate targeting of chemoprophylaxis [114]. 
PROGNOSIS 
 Prognosis of acute DILD may be satisfactory, if the 
diagnosis is performed early. Therefore, a full recovery 
could be achieved. On the other hand, failure to recognize a 
drug-mediated lung disease can lead to significant morbidity 
and mortality. The prognosis is variable and depends on the 
specific drug and underlying clinical, physiologic, and 
pathologic severity of the lung disease. Typical 
complications of DILD are pulmonary fibrosis and 
respiratory failure requiring mechanical ventilation. 
Unfortunately, if the initiating injury or abnormal repair 
from injury is not halted, progressive tissue damage can lead 
to worsening physiologic impairment and even death. 
 The prognosis does not seen to be linked to the severity 
of the initial clinical picture or to the nature of the 
underlying neoplastic disorder, but to the degree of the 
pulmonary fibrosis [114]. The mortality in acute amiodarone 
pulmonary toxicity approaches 40-50%, despite drug 
withdrawal and corticosteroid therapy. Overall, the mortality 
in amiodarone pulmonary toxicity is less than 10% in 
ambulatory patients, but it is higher (20-33%) in patients 
who are diagnosed later or who require admission to the 
hospital for this condition [101, 115]. In methotrexate lung, a 
mortality rate of 15% in one series underlines the need for 
careful management of this condition [116]. 
CONCLUSIONS 
 Now there are over 450 drugs recognizing as being 
implicated in interstitial lung disease. At present, there is no 
consensus for a definite diagnostic workup approach in 
patients with a suspicion of diffuse DILD. Clinical and 
radiographic features of diffuse DILD are often difficult to 
distinguish from other causes of diffuse lung disease (e.g. 
infections, lung involvement of an underlying malignancy, 
pulmonary edema, connective tissue disease), and there are 
no signs, symptoms, laboratory or radiologic data that could 
be considered as pathognomonic. 
 Therefore, it is important for physicians to be familiar 
with iatrogenic diseases for which their patients are at risk. 
Despite better appreciation of DILD, patients may still die 
from acute or chronic DILD [117, 118]. DILD is preventable 
to a certain extent, and sources of improvement include 
better information to patients, avoidance of certain drugs in 
allergic patients, and earlier diagnosis [118, 119]. Serial lung 
function testing are still considered useful in patients on 
bleomycin, less so in those on amiodarone or methotrexate 
[120,121]. 
 It is evident that DILD represent a very heterogenous 
group of lung disease representing one of the fundamental 
injurious responses of the lung. However, the pathogenetic 
mechanism underlying DILD are still mostly unknown, 
especially in humans. Most experimental studies have been 
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conducted with animals exposed to drugs, and these 
reactions cannot be directly extrapolated to human lung. 
Another limitation for studying DILD in human lung is the 
different occurrence of those diseases. It is very difficult to 
gather large numbers of patients/samples without 
international collaboration involving several specialities 
[74]. A systematic collection of human lung tissue and cell 
material would significantly improve the clinical-
radiological-histopathological interpretation especially if 
combined with experimental in vitro studies in cells 
established from human lung. 
 With an increasing number of therapeutic drugs available 
for use, the list of drugs that is responsible for severe 
pulmonary disease also grows. Genetic polymorphism of 
drug-metabolizing enzymes, particularly of the cytochrome 
P450 superfamily of enzymes, influences individual drug 
efficacy and safety through the alteration of 
pharmacokinetics and disposition of drugs. In the future 
genotyping should be considered to identify patients who are 
at high risk of severe toxic responses, in order to guide 
appropriate individual dosage. Both clinical and genetic risk 
stratification may lead to more accurate prevention of DILD 
in the future. 
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ADR = Adverse drug reactions 
ARDS = Acute respiratory distress syndrome 
BAL = Broncho-alveolar lavage 
BOOP = Bronchiolitis obliterans organizing pneumonia 
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DILD = Drug induced interstitial lung disease 
DLCO = Diffusing capacity 
FEV1 = Forced expiratory volumen in one second 
FVC = Forced vital capacity 
HP = Hypersensitivity pneumonitis 
HRCT = High resolution computed tomography 
ILD = Interstitial lung disease 
INF = Interferon 
NSAIDs = Nonsteroidal anti-inflammatory drugs 
NSIP = Non-specific interstitial pneumonia 
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TNF = Tumor necrosis factor 
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